Roche’s Actemra, Regeneron’s Kevzara get U.K.’s favor in COVID-19 after examine reveals 24% fall in loss of life risk
The concern of whether or not very seriously ill COVID-19 individuals can gain from anti-inflammatories
The concern of whether or not very seriously ill COVID-19 individuals can gain from anti-inflammatories